What is Lifesci Capital’s Forecast for TARA Q1 Earnings?

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities research analysts at Lifesci Capital issued their Q1 2025 earnings estimates for shares of Protara Therapeutics in a research note issued on Tuesday, March 11th. Lifesci Capital analyst C. Zhu forecasts that the company will post earnings of ($0.37) per share for the quarter. Lifesci Capital has a “Outperform” rating and a $22.00 price objective on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. Lifesci Capital also issued estimates for Protara Therapeutics’ Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($1.93) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.77) EPS and FY2026 earnings at ($2.67) EPS.

Several other analysts also recently commented on the stock. Guggenheim reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th. Cantor Fitzgerald started coverage on shares of Protara Therapeutics in a report on Friday. They issued an “overweight” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Thursday, March 6th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $22.50.

Protara Therapeutics Trading Up 7.2 %

NASDAQ:TARA opened at $4.31 on Thursday. The company’s 50 day moving average is $4.42 and its two-hundred day moving average is $3.47. The company has a market cap of $88.92 million, a PE ratio of -1.53 and a beta of 1.69. Protara Therapeutics has a twelve month low of $1.60 and a twelve month high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last released its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.09.

Hedge Funds Weigh In On Protara Therapeutics

Large investors have recently made changes to their positions in the company. HBK Investments L P acquired a new position in Protara Therapeutics during the fourth quarter worth $106,000. Squarepoint Ops LLC acquired a new position in Protara Therapeutics during the fourth quarter worth $110,000. Dimensional Fund Advisors LP acquired a new position in Protara Therapeutics during the fourth quarter worth $111,000. Bailard Inc. acquired a new position in Protara Therapeutics during the fourth quarter worth $157,000. Finally, XTX Topco Ltd acquired a new position in Protara Therapeutics during the third quarter worth $60,000. 38.13% of the stock is currently owned by institutional investors and hedge funds.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.